PeopleBio, Inc. is a South Korea-based biotechnology and in vitro diagnostics company specializing in the development of blood-based diagnostic assays and screening tools for neurodegenerative diseases and protein-misfolding disorders. The company develops and commercializes diagnostic products powered by its proprietary Multimer Detection System (MDS) platform, which selectively detects and measures oligomeric and aggregated multimeric proteins in human plasma. PeopleBio operates primarily in the medical devices and molecular diagnostics sector, serving hospitals, commercial clinical laboratories, specialized clinics, and health screening centers.
The company's product and service portfolio includes in vitro diagnostic test kits for neurodegenerative conditions, notably the InBlood / InSparq Alzheimer's disease blood test kit designed for the early detection and risk assessment of Alzheimer's disease through the quantification of oligomeric amyloid-beta (OA-beta) in blood plasma; research-use and clinical diagnostic assays targeting alpha-synuclein multimers for the early detection and monitoring of Parkinson's disease; diagnostic development pipelines for tau protein aggregation, amyotrophic lateral sclerosis (ALS), and diabetes-related neurodegenerative pathologies; specialized laboratory diagnostic testing and sample analysis services for healthcare institutions; and digital healthcare applications supporting cognitive screening and preventive memory health management.
In recent strategic and operational developments, PeopleBio has actively expanded its commercialization footprint for its blood-based Alzheimer's diagnostic assay across domestic and international markets. The company has secured supply and distribution agreements across several Asia-Pacific markets, including Southeast Asian territories, while pursuing regulatory approvals and clinical partnerships in Europe and North America to facilitate global market entry. Additionally, PeopleBio has advanced clinical evaluations for its early-stage Parkinson's disease blood diagnostic pipeline and expanded collaborations with healthcare networks, diagnostic centers, and digital health partners to integrate blood-based biomarker screening into routine health examination programs.
Founded in 2002, PeopleBio, Inc. is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and is listed on the Korean Securities Dealers Automated Quotations (KOSDAQ) under the ticker symbol 304840.